impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

Clinical aspects

 

Clinical features of systemic sclerosis patients with anti-RNA polymerase III antibody in a single centre in Spain

1, 2, 3, 4, 5, 6, 7, 8

 

  1. Unit of Systemic Autoimmune Diseases, Department of Internal Medicine, Hospital Universitari Parc Taulí, Universitat Autònoma de Barcelona, Sabadell, Barcelona, Spain.
  2. Unit of Systemic Autoimmune Diseases, Institut de Recerca Vall d’Hebron, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Spain. alguille@vhebron.net
  3. Department of Inmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain.
  4. Unit of Systemic Autoimmune Diseases, Institut de Recerca Vall d’Hebron, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Spain.
  5. Unit of Systemic Autoimmune Diseases, Institut de Recerca Vall d’Hebron, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Spain.
  6. Unit of Systemic Autoimmune Diseases, Department of Internal Medicine, Hospital Universitari Parc Taulí, Universitat Autònoma de Barcelona, Sabadell, Barcelona, Spain.
  7. Unit of Systemic Autoimmune Diseases, Institut de Recerca Vall d’Hebron, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Spain.
  8. Unit of Systemic Autoimmune Diseases, Institut de Recerca Vall d’Hebron, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Spain.

CER11630
2019 Vol.37, N°4 ,Suppl.119
PI 0041, PF 0048
Clinical aspects

Free to view
(click on article PDF icon to read the article)

PMID: 30767873 [PubMed]

Received: 19/08/2018
Accepted : 30/10/2018
In Press: 11/02/2019
Published: 03/10/2019

Abstract

OBJECTIVES:
To evaluate the clinical features and survival of patients with positive anti-RNA polymerase III (anti-RNAP III) in a Spanish single centre.
METHODS:
We analysed 221 patients with SSc according to LeRoy and Medsger criteria. Twenty-six patients with positivity for anti-RNAP III antibodies were compared with 195 negative patients. Epidemiological, clinical, immunological features and survival were analysed.
RESULTS:
In patients with anti-RNAP III positivity diffuse cutaneous SSc (dcSSc) subset was the most prevalent (20, 76.9% vs. 35, 17.9%, p < 0.001), with shorter diagnosis delay (4.11 ± 7.34 years vs. 6.77 ± 9.22 years, p = 0.005). Patients with anti-RNAP III antibodies had higher frequency of arterial hypertension (13, 50% vs. 55, 28.2%, p = 0.024), scleroderma renal crisis (SRC) (3, 11.5% vs. 3, 1.5%, p = 0.023), arthritis (9, 34.6% vs. 35, 17.9%, p = 0.046), tendon friction rubs (4, 15.4% vs. 1, 0.5%, p = 0.001) and contractures (5, 19.2% vs. 10, 5.1%, p = 0.02). There were no differences found in the presence of cancer or in global survival. In the multivariate survival analysis, severe interstitial lung disease (ILD) (HR: 8.61, 95%CI 3.40 – 21.81), pulmonary arterial hypertension (PAH) (HR: 4.05, 95%CI 1.42 – 11.61) and SRC (HR: 17.27, 95%CI 3.36 – 88.97) were the only factors associated with poor prognosis.
CONCLUSIONS:
In this cohort anti-RNAP III antibodies are related with dcSSc subset, shorter diagnostic delay and higher prevalence of musculoskeletal involvement, arterial hypertension and SRC. ILD, PAH and SRC were independent prognostic factors.

Rheumatology Article